OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes by utilising the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in combination with chemotherapy.

OncoSil Medical’s lead product, OncoSil™, is a brachytherapy device which has received CE Marking approval, providing marketing authorisation in both the EU and the UK.  The device is approved for use in New Zealand, Hong Kong, Switzerland, Turkey and Israel.  OncoSil™ is designated as a breakthrough device in both Europe and the United States¹.

We believe in our technology and its ability to have a truly positive impact in Oncology.

OncoSil™ technology is not available in all geographies. If you are a healthcare professional, please refer to our website for information about our technology and indications.

Website link: oncosil.com

References: 1. US Food and Drug Administration (FDA) Breakthrough Device Designation. March 2020. The British Standards Institute (BSI) designated the device as a breakthrough product under MEDDEV. April 2020.


Health Care

Life Sciences

Medical Devices

OncoSil Medical

Nigel Lange

Antonio Ponce Cuesta

Renzo Dicarlo

Jon Bell

Christian Dal Cin

Leadership Team

Clinical and Medical Affairs

��

Teams at OncoSil Medical

Leadership Team

Clinical and Medical Affairs

��������

Teams at OncoSil Medical

Leadership Team

Clinical and Medical Affairs

��